Press release
Ovarian Cancer Pipeline Expands with 180+ Companies and 200+ Emerging Therapies, Finds DelveInsight | Genentech, Genmab, AstraZeneca, GSK, Merck, Novartis, Allarity Therapeutics
Ovarian Cancer Drug Insights
Explore the latest breakthroughs in the Ovarian Cancer treatment landscape. Learn more about the evolving Ovarian Cancer pipeline today @ https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Ovarian Cancer Pipeline Report
• April 2025: Full FDA approval of mirvetuximab soravtansine-gynx (Elahere) for advanced, platinum-resistant ovarian cancer whose tumors overproduce FR-α, based on MIRASOL clinical trial results.
• June 2025: The FDA granted fast track designation to PHST001, an investigational anti-CD24 monoclonal antibody from Pheast Therapeutics, for advanced platinum-resistant or platinum-sensitive ovarian cancer.
• June 2025: The FDA granted fast-track designation to CHM CDH17, a novel CAR-T therapy from Chimeric Therapeutics relevant to solid tumor therapy innovation including ovarian cancer.
• June 2025: Dostarlimab-gxly (Jemperli) plus platinum-based chemotherapy followed by maintenance niraparib demonstrated statistically significant improvement in progression-free survival in the Phase 3 FIRST/ENGOT-OV44 trial.
• August 2025: The FDA granted accelerated approval to the combination therapy of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC).
• Ovarian cancer is the leading cause of death among gynecological cancers, often diagnosed at advanced stages due to nonspecific symptoms like bloating and abdominal discomfort.
• In 2024, nearly 37.6K incident cases of high- and low-grade serous ovarian cancer were reported in the 7MM, with the United States accounting for the highest share.
• The leading companies in this space include Pfizer, Daiichi Sankyo, Astellas Pharma, AstraZeneca, AbbVie, Genmab, GSK, Verastem, Merck, Novartis, and Allarity Therapeutics.
Download for updates and the latest revolution in Ovarian Cancer care @ https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Ovarian Cancer Emerging Drugs Profile
• Atezolizumab: Genentech
Atezolizumab is a monoclonal antibody currently being evaluated in Phase III clinical trials for the treatment of ovarian cancer. It belongs to a class of immunotherapies designed to target the PD-L1 protein, aiming to enhance the immune system's ability to detect and fight cancer cells.
• Stenoparib: Allarity Therapeutics
Stenoparib is a unique therapeutic candidate that inhibits PARP and blocks Wnt pathway activation. Phase II trial data to date indicates that stenoparib exhibits much less myelotoxicity than existing FDA-approved PARP inhibitors. Currently, the drug is in the Phase II stage of development for treating Advanced Ovarian Cancer.
• ATX-295: Accent Therapeutics
ATX-295 is an investigational small-molecule therapy that serves as a selective inhibitor of KIF18A, a mitotic kinesin protein essential for cell division in cancers with chromosomal instability. By targeting this pathway, ATX-295 induces mitotic arrest and tumor cell death while sparing normal cells. It is currently in Phase I/II clinical development.
For more information on the Ovarian Cancer Emerging Drugs Profile, download DelveInsight's comprehensive Ovarian Cancer Pipeline Insight report @ https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
The Ovarian Cancer Pipeline Report Provides
• Detailed insights about companies developing therapies for Ovarian Cancer, covering over 200 pipeline drugs in various developmental stages.
• Segmented therapeutic candidates categorized into early-stage, mid-stage, and late-stage of development for Ovarian Cancer treatment.
• Ovarian Cancer drugs under development based on route of administration (e.g., intravenous, oral), target receptor, and molecule type (monoclonal antibodies, small molecules, gene therapies).
• Detailed analysis of collaborative activities such as mergers and acquisitions, licensing agreements, and regulatory designations granted to new therapies.
Learn more about Ovarian Cancer drug opportunities in our comprehensive pipeline report @ https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Ovarian Cancer Companies and Competitive Landscape
There are 180+ key companies, including Pfizer, Daiichi Sankyo, Astellas Pharma, AstraZeneca, AbbVie, Genmab, GSK, Verastem, Merck, Novartis, and Allarity Therapeutics, developing therapies for Ovarian Cancer. These players are shifting the standard of care from platinum-based chemotherapy toward next-generation targeted agents, antibody-drug conjugates (ADCs), and immunotherapy combinations.
DelveInsight's Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under ROAs such as:
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Ovarian Cancer products have been categorized under various Molecule types such as:
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Discover the latest advancements in Ovarian Cancer treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Scope of the Ovarian Cancer Pipeline Report
• Coverage: Global.
• Ovarian Cancer Companies: AstraZeneca, AbbVie, Genmab, GSK, Verastem, Daiichi Sankyo, Merck, Novartis, Allarity Therapeutics, and others.
• Ovarian Cancer Therapies: Atezolizumab, Tisotumab Vedotin, Stenoparib, PHST001, CHM CDH17, and others.
• Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination.
• Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.
Table of Contents
• Introduction
• Executive Summary
• Ovarian Cancer: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Ovarian Cancer - DelveInsight's Analytical Perspective
• Late Stage Products (Phase III)
• Mid Stage Products (Phase II)
• Early Stage Products (Phase I)
• Preclinical and Discovery Stage Products
• Inactive Products
• Ovarian Cancer Key Companies
• Ovarian Cancer Key Products
• Ovarian Cancer Unmet Needs
• Ovarian Cancer Market Drivers and Barriers
• Ovarian Cancer Future Perspectives and Conclusion
• Ovarian Cancer Analyst Views
• Appendix
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ovarian Cancer Pipeline Expands with 180+ Companies and 200+ Emerging Therapies, Finds DelveInsight | Genentech, Genmab, AstraZeneca, GSK, Merck, Novartis, Allarity Therapeutics here
News-ID: 4475355 • Views: …
More Releases from DelveInsight
Pain Management Devices Market Poised to Reach USD 32.19 Billion by 2034 with a …
The global pain management devices market is witnessing significant transformation, propelled by the rising prevalence of chronic pain conditions, a strategic shift away from opioid-based therapies, and rapid technological integration such as AI-driven neuromodulation and wearable solutions.
Key Takeaways
• February 2026: CURAPOD raised USD 2.2 million in a pre-series A funding round to scale its wearable pain management technology.
• May 2025: Matri launched Matri Pro, a wearable device designed to provide…
Contraceptive Devices Market Projected to Reach USD 32.8 Billion by 2032, Driven …
The global contraceptive devices market is poised for robust expansion, fueled by increasing awareness of family planning, demographic shifts such as delayed parenthood, and the continuous innovation in long-acting reversible contraceptives (LARCs) that offer high efficacy and fewer side effects across diverse patient populations.
Key Takeaways
• The global contraceptive devices market is projected to grow from approximately USD 20.2 billion in 2024 to nearly USD 32.8 billion by 2032, reflecting a…
Trauma Fixation Devices Market Set for Steady Growth at 6.01% CAGR Through 2032: …
The global trauma fixation devices market is poised for strong, sustained expansion, driven by rising incidence of road accidents and trauma cases, growing volumes of orthopedic surgeries, and rapid adoption of advanced fixation technologies including bioabsorbable implants, minimally invasive systems, and AI-assisted surgical tools across key geographies.
Key Takeaways
• The global trauma fixation devices market is projected to grow from USD 8,073.28 million in 2024 to USD 12,795.77 million by 2032,…
Cystic Fibrosis Clinical Trial Pipeline Expands as 50+ Pharma Companies Progress …
DelveInsight's "Cystic Fibrosis - Pipeline Insight, 2026" report provides comprehensive insights about 50+ companies developing 55+ pipeline drugs in the Cystic Fibrosis pipeline landscape. It covers the Cystic Fibrosis pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Cystic Fibrosis treatment landscape.…
More Releases for Ovarian
Ovarian Cancer Diagnostics Market Size: 2033 Statistics
The Ovarian Cancer Diagnostics market is expected to grow from an estimated USD 4814.5 million in 2024 to USD 7795.1 million in 2033, at a CAGR of 5.50%.
The ovarian cancer diagnostics market plays a critical role in the early detection and management of ovarian cancer, one of the most common and lethal gynecological cancers worldwide. Ovarian cancer is often diagnosed at an advanced stage due to the lack of noticeable…
Ovarian Cancer Market Size, Future Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Ovarian Cancer Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth.
Browse…
How deadly is Ovarian Cancer?
Ovarian Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025
Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body.
The global Ovarian Cancer Treatment Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025,…
Ovarian Cancer Drug Pipeline Review H1 2017
Pharmaceutical guide Ovarian Cancer - Pipeline Review H1 2017 guide reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. Report also provides an overview of the Ovarian Cancer (Oncology) pipeline landscape. Report provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and…
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports.
Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in…
